Medicus Pharma Ltd. announced the appointment of Huma Qamar, MD as the Chief Scientific Officer &Head of R&D Program. Dr. Qamar has worked in the clinical research field for some of the most renowned Ivy league institutions such as Yale University, Harvard University and the University of Pennsylvania. She has robust experience in developing Phase I-IV clinical protocols and execution of clinical studies, FDA inspections, billing and compliance audits, and medical affairs team management.

She has expertise in multiple therapeutic areas, including Oncology (Heme-Onc, CAR-T, rare tumors, sarcoma, melanoma, Women's health, GU &GI, fetal oncology), gene therapy, vaccines, rheumatology, dermatology, neurology, cardiology, hepatology, and infectious diseases. Dr. Qamar was most recently serving as the Head of Clinical Development &Clinical Operations at Ocugen Inc. The company also announced election of James P. Quinlan, Medicus Chief Financial Officer, as Chairman of the Board, Skinject, Inc, the wholly owned subsidiary of Medicus, along with Dr. Edward J Brennan, the Chief Medical Officer of the company, and Carolyn Bonner, the President of company, as members of the Skinject, Inc, Board of Directors.